Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-07-26

FDA Approved: BORTEZOMIB — Original Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved BluePoint Laboratories' original generic application for bortezomib, a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bortezomib (bortezomib)

Snippet

ORIG AP for BORTEZOMIB (BORTEZOMIB)